Literature DB >> 2950813

Response to isoantigens and mitogens in the cat: effects of cyclosporin A.

C R Gregory, N J Taylor, N H Willits, G H Theilen.   

Abstract

Growing interest in the use of domesticated cats to study immune-mediated disease and in the research and clinical application of organ and tissue transplantation provided the need for in vitro assays estimating histocompatibility and cell-mediated immunity. In the present study, a whole-blood lymphocyte-stimulation microassay and mixed lymphocyte-response assay were adapted and used to measure significant responses from feline lymphocytes to mitogen and lymphocyte-defined histocompatibility antigens. The addition of cyclosporin A to whole-blood lymphocyte-stimulation microassay and mixed lymphocyte-response assay produced similar non-cytotoxic decrease in lymphocyte responses seen in other species.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2950813

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  Effect of recombinant human interferon-alpha in vitro and in vivo on mitogen-induced lymphocyte blastogenesis in cats.

Authors:  R C Weiss; T Oostrom-Ram
Journal:  Vet Immunol Immunopathol       Date:  1990-02       Impact factor: 2.046

Review 4.  Feline immune system.

Authors:  D S Lin
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.268

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.